WuXi Biologics receives GMP certification from Brazil's ANVISA

▴ WuXi Biologics receives GMP certification from Brazil's ANVISA
The positive assessment from ANVISA reaffirms WuXi Biologics' strong commitment to offering partners a global manufacturing network of the highest standard

WuXi Biologics, a global company with leading open-access biologics technology platforms, today announced that it has received the Good Manufacturing Practice (GMP) certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The positive assessment from ANVISA reaffirms WuXi Biologics' strong commitment to offering partners a global manufacturing network of the highest standard.

This is WuXi Biologics' third GMP certification from drug regulatory authorities, and distinguishes it as the first company in China to receive authorizations from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and ANVISA to manufacture biologics. To date, WuXi Biologics' facilities in Wuxi city, Shanghai and Suzhou have passed a total of six GMP inspections conducted by these regulatory agencies.

"We are very excited to have reached another regulatory milestone during this challenging year. This achievement once again demonstrates WuXi Biologics' high-quality services, which have been widely recognized by regulatory authorities. We owe this achievement to our partners' trust in our capabilities and our team's tireless commitment to excellence," commented Dr Chris Chen, CEO of WuXi Biologics. "As outsourcing demand increases around the world, we have made huge strides in expanding our services globally and plan to increase our total biomanufacturing capacity to 300,000 liters after 2023. WuXi Biologics will continue to enable our global partners throughout the development and manufacturing process to provide life-saving treatments to patients worldwide."

WuXi Biologics, a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients. As of June 30, 2020, there were a total of 286 integrated projects, including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 300,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

Tags : #WuXiBiologics #LatestNewsonWuXiBiologics28thDec #LatestPharmaNews28thDec #LatestGMPCertification #USFDA #EuropeanMedicinesAgency

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025
Maharashtra’s Healthcare Betrayal: Why Are Crucial Funds Going Unused?February 06, 2025
1vision, 1 mission: Avaada Foundation’s CSR initiatives are powering communities and delivering sustainable progress across 5 key focus areasFebruary 06, 2025
Top 5 Technology Brands that are Transforming the Cancer Care Journeys for Hospitals and PatientsFebruary 06, 2025
Women's Wellness brand NUA Raises Rs 35 Crore in Pre-Series C led by Mirabilis Investment TrustFebruary 06, 2025
8 Effective Ways to Minimize Postpartum ComplicationsFebruary 06, 2025
Does Where You Live Decide Your Fate? The Urban-Rural Breast Cancer Divide in IndiaFebruary 06, 2025
Nepal leads the world with largest pictorial health warnings on all tobacco productsFebruary 05, 2025
Fleetguard Filters Private Limited Recognized for Excellence in CSR at Navabharat’s 4th CSR ConclaveFebruary 05, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Ashok Leyland Reinforces ESG Commitment, Ranked No. 1 Globally in Sustainalytics’ RatingsFebruary 04, 2025
Calcium Supplements: Do You Really Need Them?February 04, 2025
Digital Diagnostics Doubles Its Foreign Publication Count in 2024February 04, 2025
World Cancer Day quotesFebruary 04, 2025
India can take a big leap in Cancer Care with Improved access to treatment and People-centered Approach: ExpertsFebruary 04, 2025
Lilly India appoints Winselow Tucker as the President and General ManagerFebruary 04, 2025
Driving Excellence in Clinical Research: ISCR's 18th Annual Conference Highlights Innovation, Technology, and Patient-CentricityFebruary 04, 2025
Southern Cross University introduces Access25 initiative to make international education more accessible to Indian studentsFebruary 04, 2025
Why Millions Suffer from Ineffective Treatments And the New Science That Can Save ThemFebruary 04, 2025